Mirabegron is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Overactive Bladder

Urinary Incontinence

• The suggested initial dosage is 25 mg taken once daily, either independently or in conjunction with solifenacin succinate 5 mg, also administered once daily.
• Depending on individual effectiveness and tolerance, the dosage may be escalated to 50 mg once daily, either as a standalone treatment or paired with solifenacin succinate 5 mg once daily.
• Swallow the tablet whole with water, with or without food, and avoid chewing, dividing, or crushing it.
• For patients with severe renal impairment or moderate hepatic impairment, the maximum recommended dose is 25 mg of Mirabegron once daily.
• Mirabegron is not recommended for patients with end-stage renal disease (ESRD) or severe hepatic impairment.

Adverse reactions associated with mirabegron are listed from most common to least common:

• Hypertension
• Nasopharyngitis
• Urinary tract infection
• Headache
• Constipation
• Sinusitis
• Dry mouth
• Nausea
• Fatigue

Hypertension (High Blood Pressure)	Nasopharyngitis	Canine Urinary Tract Infection	Headache
Constipation	Sinusitis	Dry Mouth	Fatigue

• Hypertension: Mirabegron may cause an increase in blood pressure. Monitor blood pressure regularly and use with caution in patients with a history of hypertension.
• Urinary Retention: Use Mirabegron with caution in patients at risk for urinary retention, including those with bladder outlet obstruction or a history of urinary retention.
• Angioedema: Cases of angioedema, including swelling of the lips, face, tongue, and throat, have been reported. Discontinue Mirabegron if angioedema occurs.
• Increased Heart Rate: Mirabegron may increase heart rate. Use with caution in patients with cardiovascular conditions and monitor for increases in heart rate.
• Myocardial Ischemia: Use with caution in patients with known cardiovascular disease, especially those with unstable angina, myocardial infarction, or arrhythmias.
• Liver Enzyme Elevations: Monitor liver function in patients with hepatic impairment, and discontinue Mirabegron if significant elevations in liver enzymes occur.